Market Newsdesk

ROCHESTER, N.Y., Nov. 24, 2020 (GLOBE NEWSWIRE) — Monro, Inc. (Nasdaq: MNRO), a leading provider of automotive undercar repair and tire services, today announced that its Board of Directors has declared a quarterly cash dividend of $.22 per share on the Company’s outstanding shares of common stock, including the shares of common stock to which the holders of the Company’s Class C Convertible Preferred Stock are entitled. The dividend is payable on December 22, 2020 to shareholders of record at the close of business on December 8, 2020.  

About Monro, Inc.

Headquartered in Rochester, New York, Monro is a chain of 1,242 company-operated stores, 97 franchised locations, seven wholesale locations and three retread facilities providing automotive undercar repair and tire sales and services. The Company operates in 32 states, serving the MidAtlantic and New England regions and portions of the Great Lakes, Midwest, Southeast and Western United States. The predecessor to the Company was founded by Charles J. August in 1957 as a Midas Muffler franchise. In 1966, Monro began to diversify into a full line of undercar repair services. The Company has experienced significant growth in recent years through acquisitions and, to a lesser extent, the opening of newly constructed stores. The Company went public in 1991 and trades on The Nasdaq Stock Market under the symbol MNRO.

CONTACT:	Kim Rudd / Tabatha Santiago
	Executive Assistant
	(585) 784-3324
	Investors and Media: Melanie Dambre / Jamie Baird
	FTI Consulting
	(212) 850-5600

NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) — Acreage Holdings, Inc. (“Acreage”) (CSE: ACRG.A.U, ACRG.B.U) (OTCQX: ACRDF, ACRHF) a vertically integrated, multi-state operator of cannabis licenses and assets in the U.S., today announced it will participate in three upcoming virtual investor conferences in November and December, 2020.

Cowen
’s 3

^rd

Annual
Boston (Virtual)
Conference: Interim Chief Executive Officer Bill Van Faasen will participate in a panel of executives from multi-state cannabis operators from the Northeast United States to discuss key issues in the Northeast and Mid-Atlantic regions at Cowen’s third annual Boston (virtual) Conference on November 30, 2020.

Cantor
Fitzgerald
Virtual
MSO Summit
: Chief Financial Officer Glen Leibowitz will participate in a virtual fireside chat at the Cantor Fitzgerald Virtual MSO Conference on December 15, 2020 to discuss current Acreage and cannabis industry issues.

MKM Cross-Sector
Virtual
Investor
Conference: Chief Operating Officer Bob Daino will participate in a virtual fireside chat at the MKM Cross-Sector Global Investor Conference on December 16, 2020 to discuss current Acreage and cannabis industry issues.

ABOUT ACREAGE

Headquartered in New York City, Acreage is a multi-state operator of cannabis ‎cultivation and retailing facilities in the U.S., including the company’s national retail store ‎brand, The Botanist. Acreage’s wide range of national and regionally available cannabis products include the award-winning Botanist brand, the highly recognizable Tweed brand, the Prime medical brand in Pennsylvania, the Innocent edibles brand in Illinois and others. Acreage also owns Universal Hemp, LLC, a hemp subsidiary dedicated to the distribution, marketing and sale of CBD products throughout the U.S. Since its founding in 2011, Acreage has focused on building and scaling operations to create a ‎seamless, consumer-focused, branded experience. More information is available at www.acreageholdings.com.

On June 27, 2019, Acreage implemented an arrangement under section 288 of the Business Corporations ‎Act (British Columbia) with Canopy Growth Corporation (“Canopy Growth”), which was subsequently amended on September 23, 2020 (the “Amended Arrangement”)‎. Pursuant to the Amended Arrangement, ‎upon ‎the occurrence (or waiver by Canopy Growth) of changes in federal laws in the United States to permit the general cultivation, distribution and possession of marijuana (as defined in the relevant legislation) or to remove the regulation of such activities from the federal laws of the United States (the “Triggering Event”), Canopy Growth will, subject to the ‎satisfaction or waiver of certain closing conditions, acquire ‎all of the issued and outstanding Class E subordinate voting shares (the “Fixed Shares”) on the basis of 0.3048 of a Canopy Growth share per ‎Fixed Share (following the automatic conversion of the Class F multiple voting shares and subject to adjustment ‎in accordance with the terms of the arrangement agreement entered into between Acreage and Canopy Growth on April 18, 2019, as amended on May 15, 2019 and on September 23, 2020.

In addition, Canopy Growth holds an option, exercisable at the discretion of Canopy Growth, to acquire all of the ‎issued and outstanding Class D subordinate voting shares (the “Floating Shares”) at the time that Canopy Growth acquires the Fixed Shares, for ‎cash or Canopy Growth shares, as Canopy Growth may determine, at a price per Floating Share based ‎upon the 30-day volume-weighted average trading price of the Floating Shares on the CSE relative to the trading price of the Canopy Growth shares at the time of the ‎occurrence or waiver of the Triggering Event, subject to a minimum price of US$6.41 per Floating Share.

For more information about the Amended Arrangement please see the Acreage proxy statement and management information circular dated August 17, 2020 (the “Circular”) and the respective ‎information circulars of each of Acreage and Canopy Growth dated May 17, 2019, which are available on ‎Acreage’s and Canopy Growth’s respective profiles on SEDAR at www.sedar.com and filed with the SEC on the EDGAR website at www.sec.gov. For additional information regarding ‎Canopy Growth, please see Canopy Growth’s profile on SEDAR at www.sedar.com.

FORWARD LOOKING STATEMENTS

This news release and each of the documents referred to herein contains “forward-looking information” and ‎‎“forward-looking statements” within the meaning of applicable Canadian and United States securities legislation, ‎respectively. All statements, other than statements of historical fact, included herein are forward-looking ‎information, including, for greater certainty, statements regarding the Amended Arrangement, including the likelihood of completion thereof, the ‎occurrence or waiver of the Triggering Event, the satisfaction or waiver of the closing conditions set out in the ‎Arrangement Agreement and other statements with respect to the proposed transactions with Canopy Growth. ‎Often, but not always, forward-looking statements and information can be identified by the use of words such as ‎‎“plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, ‎or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, ‎‎‎“would”, “might” or “will” be taken, occur or be achieved. ‎

Forward-looking statements or information involve known and unknown risks, uncertainties and other ‎factors which may cause the actual results, performance or achievements of Acreage or its ‎subsidiaries to be materially different from any future results, performance or achievements expressed or ‎implied by the forward-looking statements or information contained in this news release. Risks, uncertainties and other factors involved with forward-looking ‎information could cause actual events, results, performance, prospects and opportunities to differ ‎materially from those expressed or implied by such forward-looking information, including, but not ‎limited to financing and liquidity risks, and the risks disclosed in the Circular, Acreage’s ‎management information circular dated May 17, 2019 filed on May 23, 2019, Acreage’s annual report on Form 10-K for the year ended ‎December 31, 2019 ‎dated May 29, 2020 and the amendment thereto on Form 10-K/A ‎dated August 14, 2020, and Acreage’s other public filings, in each case filed with the SEC on the EDGAR website at www.sec.gov and with ‎Canadian securities regulators ‎and available on the issuer profile of Acreage on SEDAR at www.sedar.com. Although Acreage has attempted to identify ‎important factors that could cause actual results to differ materially from those contained in forward-looking ‎information, there may be other factors that cause results not to be as anticipated, estimated or intended. ‎

Although Acreage believes that the ‎assumptions and factors used in preparing the forward-looking information or forward-looking ‎statements in this news release are reasonable, undue reliance should not be placed on such information ‎and no assurance can be given that such events will occur in the disclosed time frames or at all. The ‎forward-looking information and forward-looking statements included in this news release are made as of ‎the date of this news release and Acreage does not undertake any obligation to publicly update such ‎forward-looking information or forward-looking information to reflect new information, subsequent events ‎or otherwise unless required by applicable securities laws.

Neither the Canadian Securities Exchange nor its Regulation Service Provider has reviewed and does not accept ‎responsibility for the adequacy or accuracy of the content of this news release.‎

Media Contact:	Investor Contact:
Howard Schacter Vice President of Communications [email protected] 917-893-5300	Steve West Vice President, Investor Relations [email protected] 917-893-5300

MISSISSAUGA, Ontario, Nov. 24, 2020 (GLOBE NEWSWIRE) — FirstOnSite Restoration, Canada’s leading independent disaster restoration services provider, has strengthened its presence in Alberta and Saskatchewan with the signing of an agreement to acquire Spectrum Restoration, a family run business since 2006.

Spectrum Restoration is a regional full-service commercial and residential restoration leader with experience managing commercial large loss projects, a focus on utilizing technology and an emphasis on customer service. Spectrum has approximately 40 employees across two locations: Lloydminster and Cold Lake, AB. It is headquartered in Lloydminster – a unique city that straddles the borders of Alberta and Saskatchewan and thus conveniently located to service commercial and residential customers in both provinces.

Spectrum Restoration has been operating for the past 14 years under the leadership of Greg and Travis Stieb. Travis Stieb, who has been instrumental in the growth and development of the commercial large loss business, will be taking on the role of Senior Project Manager, Complex Commercial Division. Rick Stephens, with an extensive background in operations management, will be assuming the role of Branch Manager for both the Lloydminster and Cold Lake locations.

“This acquisition represents an important expansion for FirstOnSite that closes a geographical service gap in the Prairies, allowing us to reach new customers and expand our coverage for our existing partners.” said Bill Moorman, SVP, Western Operations, FirstOnSite Restoration. “By adding Travis to our commercial loss team, we gain a very talented project manager with a reputation for doing what’s right for customers and employees. We see a strong alignment in values in many ways and believe he will be a great addition to FirstOnSite.”

“Spectrum Restoration complements FirstOnSite’s business very nicely and fits in with our strategic focus on growing our commercial capabilities across the country,” said Dave Demos, CEO. “Spectrum is well known for its residential restoration services and its exceptional abilities to manage large loss commercial projects. Combined with the strength that FirstOnSite’s corporate structure offers, we anticipate this acquisition will generate significant growth in the region.”

“FirstOnSite has been a trusted partner and we are thrilled at the opportunity to join forces with a large, sophisticated company that shares the same passion for large loss restoration,” said Travis Stieb, Spectrum Restoration. “With the systems and infrastructure of a large corporation, not only will FirstOnSite provide support and the ability to scale up when large loss disasters hit, it will provide our employees with room for advancement, giving them more potential in their career paths.”

The deal is scheduled to close on December 1, 2020. Terms of the transaction, including purchase price, were not disclosed.

About FirstOnSite Restoration

Founded in 2007 and based in Mississauga, ON, FirstOnSite Restoration Limited is one of the largest emergency restoration and reconstruction service providers in North America. FirstOnSite Restoration is a subsidiary of FirstService Corporation. In 2016, FirstOnSite joined forces with Interstate Restoration, a leading disaster restoration services provider for commercial enterprises in the U.S. With greater than 2,000 employees and more than 75 locations, FirstOnSite Restoration and Interstate assist property owners and businesses in recovering from fire, flood, natural and human-caused disasters.

For more information visit: www.firstonsite.ca or call 1.877.778. 6731, and follow @firstonsite on Twitter at www.twitter.com/firstonsite.

Press Contact:

Christine Alfred
MAVERICK
(416) 577-4052
[email protected]

NORTHRIDGE, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) — (via InvestorWire) – Innovative Payment Solutions (“Innovative” or the “Company”) (OTCQB: IPSI), a U.S.-based fintech company building a 21st century digital payment solution, today announces the launch of a joint marketing venture with social marketing company Planet Hunny, Inc (“Planet Hunny”) to help expand the Company’s reach to the U.S.-based Latino community of 17 million people.

The joint marketing venture will leverage Planet Hunny’s influencers in order to reach specific Latin-American markets to expand Innovative’s access to Hispanic users and also will work toward the cross-pollination of all customers in Innovative’s network, introducing them to Planet Hunny.

Innovative brings to the joint marketing venture its extensive experience from the five years of its operations in Mexico, with over 2 million local users and a built-up fintech ecosystem in place that uses multiple devices in order to help meet the needs of both consumers and service providers.

Planet Hunny has established relationships with a variety of influencers and celebrities in sports, modeling and the pageantry world and is able to reach audiences of between 10 million and 20 million people in these niches, resulting in a scope of more than 35 million total users. Planet Hunny’s association with Being Latino, one of the nation’s leading U.S. Hispanic social media marketing companies, should also be particularly invaluable, and it is expected that its influencer and celebrity force will act as a traffic generator for the Innovative platform and ecosystem through a joint collaboration and marketing campaign.

“We see a tremendous opportunity for Innovative to reach new users, including millennials and Gen Z, by entering into this relationship,” stated William Corbett, president and CEO of Innovative. “Planet Hunny’s network and marketing expertise will provide us with additional exposure to Latino communities while approaching vertical markets. We believe it is a perfect tool to reach more users and offer our services to targeted underbanked and unbanked Latin-American users. Planet Hunny has built a solid team of seasoned professionals with a strong advisory board. We are extremely excited about this engagement.”

“Planet Hunny is a believer in execution,” added Jeff Vanderpol, president and founder of Planet Hunny. “Our companies have identified multiple points where our interests are mutually aligned, and we view this engagement as beneficial to our respective business models. Innovative will be our major fintech client, and we are looking forward to leveraging our expertise, merging our efforts and serving the unbanked/underbanked communities together.”

About
Planet
Hunny

Planet Hunny is a content platform that aggregates content from social influencers and affiliate partners to create a unique discovery experience for users. The company is also building a powerful database with new insights and trends daily, while creating a formidable customization “mirror” of user preferences based on the ultimate data analytics to offer products and services reflecting user desires. Planet Hunny is a proud Host Channel Partner of Being Latino – the No.2 most engaging branded content publisher in the U.S. on Facebook year-to-date. (http://www.Hunny.io/)

About Innovative Payment Solutions, Inc

Innovative Payment Solutions, Inc. (“Innovative”) strives to offer cutting-edge digital payment solutions for consumers and service providers. Innovative’s ecosystem will span multiple devices, such as self-service kiosks, mobile applications and POS terminals, offering alternative payment methods, including money remittance, to meet the needs of consumers and service providers. (https://www.innovatepaysolve.com)

SAFE HARBOR STATEMENT

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statement of historical fact contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate, “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should” or “will” or the negative of these terms or other comparable terminology and include statements regarding expanding the Company’s reach to the U.S.-based Latino community of 17 million people; Planet Hunny’s association with Being Latino being particularly invaluable; Being Latino’s influencer and celebrity force acting as a traffic generator for the Innovative platform and ecosystem; the opportunity for the Company to reach new users, including millennials and Gen Z, by entering into the relationship; and Planet Hunny being a perfect tool to reach more users and offer the Company’s services to targeted underbanked and unbanked Latin-American users. These forward-looking statements are based on expectations and assumptions as of the date of the press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, our ability to leverage Planet Hunny’s influencers to expand the Company’s reach to the U.S.-based Latino community of 17 million people; our ability to use Planet Hunny’s association with Being Latino to generate traffic for the Company’s platform and ecosystem; our ability to use Planet Hunny’s network and marketing expertise to reach new users, including millennials and Gen Z; the contribution of Planet Hunny to reaching more users and offer the Company’s services to targeted underbanked and unbanked Latin-American users; our ability to position the Company for future profitability; the duration and scope of the COVID-19 outbreak worldwide, including the impact to the economies in California and Mexico; and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended Dec. 31, 2019, and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and the Company undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events or otherwise, except as required by law.

For investor inquiries, please call (818) 864-4004 or email: [email protected].

Corporate Communications:

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

SAN DIEGO, Nov. 24, 2020 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual investor event to provide a review of the Company’s oral, potent and selective menin inhibitor, KO-539, following the oral presentation of preliminary clinical data at the 62nd American Society of Hematology (ASH) Annual Meeting. The event will feature members of the Kura management team along with two of the investigators from KOMET-001, an ongoing Phase 1/2A clinical trial of KO-539. The virtual event will take place at 2:00 p.m. ET / 11:00 a.m. PT on Saturday, December 5, 2020.

A live video webcast of the event will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available shortly after the conclusion of the event.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Company’s pipeline is also highlighted by KO-539, a potent and selective menin inhibitor currently in a Phase 1/2A clinical trial (KOMET-001) in patients with relapsed or refractory acute myeloid leukemia. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
[email protected]

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
(858) 356-5932
[email protected]

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
[email protected]

TORONTO, Nov. 24, 2020 (GLOBE NEWSWIRE) — Mandalay Resources Corporation (“Mandalay” or the “Company”) (TSX: MND, OTCQB: MNDJF) is pleased to provide an update on encouraging results from the Aurora extension and delineation drill programs at its Björkdal mine. These results highlight the open nature of the plunge extensions and an emerging new high-grade domain.

Aurora


Drilling


Highlights

Extensional drilling to the east and down plunge:

• 4.
  8
  g/t
  gold
  over a true width of
  2
  .
  47
  m in MU20-007; and
• 2.7
  g/t
  gold
  over a true width of
  2
  .
  82
  m in MU20-016

Definition drilling to the east:

• 8.1
  g/t
  gold
  over a true width of
  2.99
  m in DOD2020-063; and
• 3.0
  g/t gold
  over a true width of
  3.4
  5
  m in DOD2020-073

Surrounding veining highlights:

• 14
  .5
  g/t gold over a true width of
  2.9
  2
  m in DOD2020-060; and
• 38.7
  g/t gold over a true width of
  0.
  59
  m in DOD2020-074; and
• 55.6
  g/t gold over a true width of 0.
  28
  m in MU20-018

Note: A full listing of significant drilling composites can be found in Tables 1 and 2 at the bottom of this document.

Dominic Duffy, President and Chief Executive Officer of Mandalay, commented, “We are pleased to report continued encouraging results from the Aurora extension program. These results come at a time when ore production from Aurora is ramping up and becoming the most significant ore source for Björkdal.”

Mr. Duffy continued, “With the exceptional grades seen at Aurora, its extension – both to the east and west – represents an important incremental step for Björkdal providing the foundation to bolster overall feed grade and extend mine life. We are also encouraged by some very high-grade intercepts of veins in close proximity to Aurora which will also be a focus of additional drilling going forward.”

Mr. Duffy continued, “With the current exploration focus turned to strategic development of other targets within Björkdal, we look forward to continuing the Aurora expansion program in early 2021.”

Mr. Duffy concluded, “Alongside this exploration release, a video has been prepared by Mr. Chris Davis, Vice President of Operational Geology and Exploration to further illustrate the detail in this press release, I would like to invite everyone to view the posted video here.”

Aurora Extensional Drilling

The Aurora Extensional Drilling has continued since Mandalay’s last Aurora update in June 2020. To the east MU20-016 returned an intercept of 2.82 m @ 2.7 g/t Au, indicating the plunge extent of Aurora is still open at depth. This was supported by MU20-013 with a reasonably well mineralized array of veining over 3.02 m at 1.6 g/t Au, typical of Aurora, intercepted approximately 60 m above. Higher in the system there has been a reinterpretation of Aurora veining due to new information mining and other drilling results. As a consequence MU20-007 was reinterpreted to include a high-grade composite of 2.47 m at 4.8 g/t Au that, combined with another previously reported intercept (MU20-018 at 7.21 m at 2.5 g/t Au) to the north, highlights a new enriched domain open to the east (see Figure 2).

Further drilling to the east within holes MU20-030 and MU20-032 did not intercept significant mineralization along the interpreted Aurora continuation however in both cases the footwall veining was enriched with 0.25 m at 23.5 g/t Au in MU20-030 and 0.96 m at 12.4 g/t in MU20-032 (see Figure 1). This could indicate a jump across structures of the gold endowment or an as yet unrecognised offset to the main Aurora structure. These results represent the furthest intercepts yet drilled to the east. Continuation of the extension campaign is expected in early 2021.

Surrounding Veining

As well as delineating and extending Aurora the drilling is providing grade information on the stacked set of veins that exist in both the footwall and hanging wall. As seen in MU20-30 and MU20-32, these veins are sometimes higher grade than Aurora and are an important addition to the production potential of the Björkdal mine. In the last Resource update for Björkdal, Aurora made up approximately 45% of metal in resource from veining above the marble contact with the remainder in the surrounding veining. Results from the surrounding veining within recent drilling can be found in Table 2 and illustrated within Figure 1.

Western


D


efinition


D


rilling

Due to the complicated nature of the veining and gold enrichment within and around Aurora, it is necessary to undertake targeted definition drilling to optimise ore extraction. From this drilling Mandalay has discovered that the Aurora system is also open to the west with encouraging intercepts following along the Frea Fault interaction such as 3.17 m at 3.0 g/t Au in DOD2020-075 and 4.66 m at 2.1 g/t Au in DOD2020-072. In this area approximately 15 additional continuous veins exist alongside Aurora with highlights of 0.59 m at 38.7 g/t Au in DOD2020-074 and 0.37 m at 31.7 g/t in DOD2020-075. As with the extension to the east, a drilling program will focus on extension along this trend in early 2021.

Figure 1. North-South Cross Section at illustrating the location and orientation of the new intercepts surrounding Aurora between 1550 E and 1650 E is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/65c1259e-a6a4-4c35-afc4-a58fe4aa3ed8. Veining and interpreted lithology is displayed at 1600 E. The DOD series of holes are drilled further to the west and are not shown on this section.

Figure 2. Longitudinal section of Aurora illustrating the location of recent extension and definition drilling results is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/98b65977-3ee7-4386-a792-d98da87f9249.

Drilling and Assaying

At Björkdal, all diamond drill core was logged and sampled by Björkdal geologists. Exploration drill hole samples (prefix MU) were sent to CRS Laboratories Oy (“CRS”) in Kempele, Finland for sample preparation and assaying. Development optimization drill hole samples (prefix DOD) were prepared and assayed at the onsite laboratory ran by Minlab AB, a subsidiary of CRS (see Technical Report dated March 30, 2020 entitled “Technical Report on the Björkdal Gold Mine, Sweden”, available on SEDAR (www.sedar.com), which contains a complete description of drilling, sampling, and assaying procedures).

Assaying was conducted utilizing the Pal1000 cyanide leaching processes. Mandalay’s rigorous QA/QC program included the use of standard reference samples, blanks, duplicates, repeats, and internal laboratory quality assurance procedures.

Qualified Person:

Chris Davis, Vice President of Operational Geology and Exploration at Mandalay Resources, is a Charted Professional of the Australian Institute of Mining and Metallurgy (MAusIMM CP(Geo)), and a Qualified Person as defined by NI 43-101. He has reviewed and approved the technical and scientific information provided in this release.

For Further Information

Dominic Duffy
President and Chief Executive Officer

Edison Nguyen
Manager, Analytics and Investor Relations

Contact:
647.260.1566

About Mandalay Resources Corporation

Mandalay Resources is a Canadian-based natural resource company with producing assets in Australia and Sweden, and care and maintenance and development projects in Chile. The Company is focused on growing production at its gold and antimony operation in Australia, and gold production from its operation in Sweden to generate near term cash flow.

Forward-Looking Statements:

This news release contains “forward-looking statements” within the meaning of applicable securities
laws,
including
statements
regarding
the
exploration
and
development
potential
of the
Aurora
Zone
(Björkdal).
Readers
are
cautioned
not
to place undue reliance on forward-looking statements. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things,
changes
in
commodity
prices
and
general
market
and
economic
conditions.
The
factors identified
above
are
not
intended
to
represent
a
complete
list
of
the
factors
that
could
affect Mandalay.
A
description
of
additional
risks
that
could
result
in
actual
results
and
developments differing
from
those
contemplated
by
forward-looking
statements
in
this
news
release
can
be found
under
the
heading
“Risk
Factors”
in
Mandalay’s
annual
information
form
dated
March 30, 2020, a copy of which is available under Mandalay’s profile at

www.sedar.com.

In addition, there can be no assurance that any inferred resources that are discovered as a result of additional
drilling
will
ever
be
upgraded
to
proven
or
probable
reserves.
Although
Mandalay
has attempted to identify important factors that could cause actual actions, events or results to differ
materially
from
those
described
in
forward-looking
statements,
there
may
be
other
factors that
cause
actions,
events
or
results
not
to
be
as
anticipated,
estimated
or
intended.
There
can be no assurance that forward-looking statements will prove to be accurate, as actual results and
future
events
could
differ
materially
from
those
anticipated
in
such
statements.
Accordingly, readers
should
not
place
undue
reliance
on
forward-looking
statements.

Table 1
. New Drilling Composites on Aurora

Drill Hole ID	From (m)	To (m)	Drill Width (m)	True Width (m)	Au Grade (g/t)	Au (g/t) over min. 3m mining width	Target
DOD2020-058	77	80.65	3.65	2.81	0.2	0.1	Western Definition
DOD2020-059	87.9	93.52	5.62	3.78	0.4	0.4	Western Definition
DOD2020-060	79.65	85	5.35	4.25	0.8	0.8	Western Definition
DOD2020-061	66.6	70.2	3.60	3.33	0.9	0.9	Western Definition
DOD2020-063	94.25	98.4	4.15	2.99	8.1	8.1	Western Definition
DOD2020-072	148.5	153.2	4.70	4.66	2.1	2.1	Western Definition
DOD2020-073	142.25	145.7	3.45	3.45	3.0	3.0	Western Definition
DOD2020-074	145.7	149.5	3.80	3.77	0.2	0.2	Western Definition
DOD2020-075	139.05	142.25	3.80	3.17	3.0	3.0	Western Definition
DOD2020-076	145.45	148.3	3.80	2.67	0.2	0.2	Western Definition
DOD2020-097	121	126.6	5.55	3.50	0.7	0.7	Western Definition
DOD2020-099	107.2	113.8	6.55	4.63	2.0	2.0	Western Definition
MU20-007	323.45	326.2	2.75	2.47	4.8	3.9	Eastern Extension
MU20-013	216.1	219.55	3.45	3.02	1.6	1.6	Eastern Extension
MU20-016	271.6	276.6	5.00	2.82	2.7	2.5	Eastern Extension
MU20-017	188.3	197.75	9.45	7.30	0.6	0.6	Eastern Extension
MU20-030	132	135.4	3.40	2.36	0.6	0.5	Eastern Extension
MU20-031	161.95	163.85	1.90	1.17	0.4	0.1	Eastern Extension
MU20-032	208.25	211.15	2.90	1.89	1.6	1.0	Eastern Extension

Notes

1. Where True widths are greater than 3 m, grades are not diluted and are presented as the grade over the composite true width.

Table 2
. New Drilling Composites Surrounding Aurora

Drill Hole ID	From (m)	To (m)	Drilled Width (m)	True Width (m)	Au Grade (g/t)	Au (g/t) over min. 3m mining width	Description
DOD2020-058	71.00	72.80	1.80	1.60	2.9	1.6	Foot Wall Veining
DOD2020-060	73.60	77.80	4.20	2.92	14.5	14.1	Foot Wall Veining
DOD2020-060	115.00	115.35	0.35	0.25	9.5	0.8	Hanging Wall Veining
DOD2020-061	52.55	60.10	7.55	6.51	2.6	2.6	Foot Wall Veining
DOD2020-061	97.30	97.70	0.40	0.31	8.9	0.9	Hanging Wall Veining
DOD2020-063	133.80	134.10	0.30	0.19	57.4	3.6	Hanging Wall Veining
DOD2020-072	83.80	84.75	0.95	0.92	9.7	3.0	Foot Wall Veining
DOD2020-072	116.10	116.50	0.40	0.31	5.9	0.6	Foot Wall Veining
DOD2020-072	157.75	158.75	1.00	0.78	4.8	1.3	Hanging Wall Veining
DOD2020-072	187.55	188.10	0.55	0.50	7.6	1.3	Hanging Wall Veining
DOD2020-072	191.50	192.00	0.50	0.49	3.8	0.6	Hanging Wall Veining
DOD2020-073	48.05	48.65	0.60	0.59	5.8	1.1	Foot Wall Veining
DOD2020-073	64.50	64.85	0.35	0.31	6.3	0.6	Foot Wall Veining
DOD2020-073	153.15	153.60	0.45	0.44	3.8	0.6	Hanging Wall Veining
DOD2020-073	178.05	179.65	1.60	1.59	4.9	2.6	Hanging Wall Veining
DOD2020-073	185.70	186.00	0.30	0.21	24.3	1.7	Hanging Wall Veining
DOD2020-074	32.70	33.30	0.60	0.59	38.7	7.6	Foot Wall Veining
DOD2020-074	131.95	132.35	0.40	0.39	16.0	2.1	Foot Wall Veining
DOD2020-074	153.70	156.10	2.40	2.15	2.0	1.4	Hanging Wall Veining
DOD2020-074	165.90	167.75	1.85	1.80	3.5	2.1	Hanging Wall Veining
DOD2020-074	185.60	185.95	0.35	0.34	6.1	0.7	Hanging Wall Veining
DOD2020-075	31.60	32.05	0.45	0.42	5.6	0.8	Foot Wall Veining
DOD2020-075	52.75	53.10	0.35	0.34	7.7	0.9	Foot Wall Veining
DOD2020-075	77.00	77.35	0.35	0.33	5.1	0.6	Foot Wall Veining
DOD2020-075	108.75	109.10	0.35	0.31	9.3	1.0	Foot Wall Veining
DOD2020-075	123.20	124.60	1.40	1.29	3.2	1.4	Foot Wall Veining
DOD2020-075	170.15	170.65	0.50	0.34	10.3	1.2	Hanging Wall Veining
DOD2020-075	180.80	181.20	0.40	0.37	31.7	3.9	Hanging Wall Veining
DOD2020-075	190.25	190.60	0.35	0.31	13.3	1.4	Hanging Wall Veining
DOD2020-076	29.88	30.25	0.37	0.27	6.1	0.5	Foot Wall Veining
DOD2020-076	51.40	52.83	1.43	1.36	1.8	0.8	Foot Wall Veining
DOD2020-076	103.00	103.35	0.35	0.29	7.4	0.7	Foot Wall Veining
DOD2020-076	117.30	117.65	0.35	0.27	12.4	1.1	Foot Wall Veining
DOD2020-076	126.15	126.50	0.35	0.32	6.5	0.7	Foot Wall Veining
DOD2020-076	157.20	157.70	0.50	0.31	5.6	0.6	Hanging Wall Veining
DOD2020-076	163.00	164.45	1.45	1.38	3.3	1.5	Hanging Wall Veining
DOD2020-076	183.35	183.70	0.35	0.31	15.0	1.6	Hanging Wall Veining
DOD2020-076	196.30	199.30	3.00	2.69	2.1	1.9	Hanging Wall Veining
DOD2020-076	201.65	202.00	0.35	0.31	5.1	0.5	Hanging Wall Veining
DOD2020-097	111.25	112.25	1.00	0.78	3.5	0.9	Foot Wall Veining
DOD2020-097	166.15	166.80	0.65	0.37	7.9	1.0	Hanging Wall Veining
DOD2020-099	112.90	113.75	0.85	0.70	4.0	0.9	Hanging Wall Veining
DOD2020-099	139.55	139.95	0.40	0.29	11.2	1.1	Hanging Wall Veining
MU20-007	229.30	230.00	0.70	0.61	2.7	0.6	Foot Wall Veining
MU20-008A	320.05	321.95	1.90	1.90	1.4	0.9	Foot Wall Veining
MU20-009A	327.05	329.00	1.95	1.07	14.5	5.2	Foot Wall Veining
MU20-009A	338.40	338.85	0.45	0.27	5.9	0.5	Foot Wall Veining
MU20-011	177.60	178.50	0.90	0.78	2.5	0.6	Foot Wall Veining
MU20-011	271.60	273.00	1.40	0.30	7.2	0.7	Foot Wall Veining
MU20-011	278.75	279.25	0.50	0.23	32.5	2.5	Foot Wall Veining
MU20-011	337.45	338.65	1.20	0.29	13.9	1.3	Hanging Wall Veining
MU20-011	362.20	362.75	0.55	0.26	6.2	0.5	Hanging Wall Veining
MU20-011	371.60	372.00	0.40	0.31	5.1	0.5	Hanging Wall Veining
MU20-012	119.70	120.00	0.30	0.29	6.5	0.6	Foot Wall Veining
MU20-014	191.30	192.15	0.85	0.78	6.2	1.6	Hanging Wall Veining
MU20-015	153.75	154.70	0.95	0.79	2.9	0.8	Hanging Wall Veining
MU20-016	27.90	28.60	0.70	0.70	3.4	0.8	Foot Wall Veining
MU20-016	224.40	224.75	0.35	0.20	12.5	0.8	Foot Wall Veining
MU20-017	167.65	168.15	0.50	0.34	5.6	0.6	Foot Wall Veining
MU20-018	114.20	114.65	0.45	0.44	3.7	0.5	Foot Wall Veining
MU20-018	194.40	195.25	0.85	0.78	4.5	1.2	Hanging Wall Veining
MU20-030	96.20	96.55	0.35	0.25	23.5	2.0	Foot Wall Veining
MU20-032	155.70	156.85	1.15	0.96	12.4	4.0	Foot Wall Veining

Notes

1. Where True widths are greater than 3 m, grades are not diluted and are presented as the grade over the composite true width.
2. Composites that are below 0.5 g/t Au when diluted to 3 m are not reported in this table.

BRYAN, Texas, Nov. 24, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 10,844,392, entitled “Materials and Methods for Producing Endostatin Fusion Polypeptides in Plant Cells,” which, amongst other claims, covers a novel expression cassette that enhances the yield of endostatin fragments and variants using iBio’s FastPharming^® System.

The claims in the patent are foundational to iBio’s work on its antifibrotic therapies given that the technologies enhance the expression and quality of endostatin-derived E4 antifibrotic peptides fused to human IgG1 when produced in plants. The Company is developing such a molecule as “IBIO-100” for the treatment of fibrotic disorders, including systemic scleroderma and idiopathic pulmonary fibrosis. The ‘392 Patent contains 19 claims and expires in June 2036.

“This patent, and the technologies it covers, advances our work on therapeutic candidates for treating fibrotic disorders by increasing the number of antifibrotic peptide variants that we may select for clinical development,” said Tom Isett, Chairman & CEO of iBio. “iBio can also apply certain claims to other IgG-based molecules manufactured using our FastPharming System, thereby creating the opportunity to secure additional intellectual property based upon composition of matter.”

iBio plans to conduct IND-enabling studies on IBIO-100 in 2021.

About
iBio
, Inc.

iBio is a global leader in plant-based biologics manufacturing. Its FastPharming^® System combines vertical farming, automated hydroponics, and glycan engineering technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services. iBio’s Glycaneering Development Service™ includes an array of new glycosylation technologies for engineering high-performance recombinant proteins. Additionally, iBio is developing proprietary products, which include IBIO-100 for the treatment of fibrotic diseases, and vaccines for infectious diseases. For more information, visit www.ibioinc.com.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding developing “IBIO-100” for the treatment of fibrotic disorders, including systemic scleroderma and idiopathic pulmonary fibrosis, securing additional intellectual property based upon composition of matter by applying certain claims to other IgG-based molecules manufactured using our FastPharming System and plans to conduct IND-enabling studies on IBIO-100 in 2021. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to conduct additional investigational new drug-enabling studies in the first half of 2021 as planned, the Company’s ability to obtain regulatory approvals for commercialization of its product candidates, including its COVID-19 vaccines, or to comply with ongoing regulatory requirements, regulatory limitations relating to its ability to promote or commercialize its product candidates for specific indications, the Company’s ability to enroll patients and complete clinical trials on time and achieve desired results and benefits as expected, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, its ability to maintain its license agreements, the continued maintenance and growth of its intellectual property portfolio, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, competition, its ability to retain its key employees or maintain its NYSE American listing, and the other risk factors discussed in the Company’s most recent Annual Report on Form 10-K and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Contact
s
:

Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
[email protected]

– Data Expected
Second Quarter
2021 –

–
The INSPIRE Trial Is
Designed
t
o
Assess
t
he Ability
o
f CAP-1002
t
o
Modulate
t
he Cytokine Storm Associated With Severe COVID-19
–

LOS ANGELES, Nov. 24, 2020 (GLOBE NEWSWIRE) — Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of a variety of diseases and disorders, announced today that the first two patients have been dosed in its Phase 2 study evaluating intravenous infusion of CAP-1002 – its lead clinical asset – using its allogeneic cardiosphere-derived cells (CDC) technology as a treatment option for patients with COVID-19. The study is now enrolling patients who have been diagnosed with SARS-CoV-2 and require supplemental oxygen. The study is being conducted at multiple sites in the United States and will enroll up to 60 patients.

“This trial represents a significant milestone for Capricor, as we expand the scope of our CAP-1002 program to treat patients with severe COVID-19. As hospitalizations continue to increase, we have a therapeutic under investigation for patients at a high-risk for significant morbidity or even death,” said Linda Marbán, Ph.D., President and Chief Executive Officer of Capricor. “It is important to remember that many patients are suffering from long term cardiac consequences from COVID-19. As CAP-1002 directly targets cardiac dysfunction, CAP-1002 potentially may also be an important tool in the treatment of the cardiac complications of COVID-19.”

Within the framework of SARS-CoV-2 pathogenesis, multiple pathways known to be CAP-1002 sensitive may serve as therapeutic targets. These targets include pro-inflammatory pathways (TNF-α, interferon γ, IL-1, and IL-6) and anti-inflammatory pathways (regulatory T cells and IL-10) that have been explored with CAP-1002 in preclinical models of myocardial ischemia, myocarditis, heart failure, muscular dystrophy and pulmonary hypertension. Given that CAP-1002 polarizes macrophages to an anti-inflammatory (healing) immunomodulatory phenotype, CAP-1002 may subsequently attenuate cytokine storm.

The INSPIRE trial (NCT04623671) is a Phase 2, randomized, double-blind, placebo-controlled study that will enroll subjects with a clinical diagnosis of COVID-19 confirmed by laboratory testing and are in severe or critical condition as indicated by life-support measures. The primary objectives of the study are to determine the safety and effectiveness of intravenously infused CAP-1002 for improving clinical outcomes in severe to critical patients with COVID-19. Eligible subjects will be randomized to either the CAP-1002 or placebo group (1:1 ratio) and undergo baseline safety and efficacy assessments approximately one to three days prior to the administration of investigational product (IP).

“We remain committed to developing therapeutic options for patients diagnosed with severe COVID-19 in parallel to the exciting developments recently reported on our exosome platform technology. We look forward to announcing more updates on these programs as they become available,” concluded Dr. Marbán.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also investigating the field of extracellular vesicles and exploring the potential of exosome-based candidates to treat or prevent a variety of disorders. We are now developing two potential vaccines for COVID-19 as part of our exosome platform. For more information, visit www.capricor.com and follow the Company on Facebook, Instagram and Twitter.

About CAP-1002

CAP-1002 consists of allogeneic cardiosphere-derived cells, or CDCs, a type of cardiac cell therapy that has been shown in pre-clinical and clinical studies to exert potent immunomodulatory activity. It is being investigated for its potential to modify the immune system’s activity to encourage cellular regeneration. The cells function by releasing exosomes that are taken up largely by macrophages and T-cells and begin a cycle of repair. CDCs have been the subject of over 100 peer-reviewed scientific publications and administered to approximately 200 human subjects across several clinical trials.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on March 27, 2020 and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 as filed with the Securities and Exchange Commission on November 13, 2020. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation.

For more information, please contact:

Media Contact:

Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
[email protected] / [email protected]
212.896.1241 / 212.896.1204

Investor Contact:

Joyce Allaire
LifeSci Advisors, LLC
[email protected]
617.435.6602

Company Contact:

AJ Bergmann, Chief Financial Officer
[email protected]
310.358.3200

Dallas, Nov. 24, 2020 (GLOBE NEWSWIRE) — Thryv Holdings, Inc. (NASDAQ:THRY), the provider of Thryv^® software, the end-to-end client experience platform for small businesses, today announced that CEO and President Joe Walsh will participate in a question and answer session at the Wells Fargo TMT Summit on December 1 at 4:40 p.m. ET.

A live webcast will be available on Thryv’s Investor Relations page at investor.thryv.com. An archived replay will be made available for a limited time at the same location following the event.

About Thryv Holdings, Inc.

The company owns the easy-to-use Thryv® end-to-end customer experience software built for small business that helps over 40,000 SaaS clients with the daily demands of running a business. With Thryv, they can get the job, manage the job and get credit. Thryv’s award-winning platform provides modernized business functions, allowing small-to-medium-sized businesses (SMB) to reach more customers, stay organized, get paid faster and generate reviews. These include building a digital customer database, automated marketing through email and text, updating business listings across the internet, scheduling online appointments, sending notifications and reminders, managing ratings and reviews, generating estimates and invoices and processing payments.

Thryv supports franchise operators and multi-location business owners with Hub by Thryv™, a software console that enables businesses managers to oversee their operations using the Thryv software.

Thryv also connects local businesses to consumer services through our search, display and social media management products, our print directories featuring The Real Yellow Pages® tagline, and our local search portals, which operate under the DexKnows.com®, Superpages.com® and Yellowpages.com URLs and reach some 35 million monthly visitors. For more information about the company, visit thryv.com.

Thryv delivers business services to more than 360,000 SMBs across America that enable them to compete and win in today’s economy.       

Learn more about Thryv on LinkedIn and Medium.

 

Media Contact:

Paige Blankenship

Thryv, Inc.

972.453.3012

[email protected]

 

Investor Contact:

Cameron Lessard 

Thryv, Inc.
    

214.773.7022 

[email protected]   

 

KJ Christopher

Thryv, Inc.

972.453.7068

[email protected]

 

###

Paige Blankenship
Thryv, Inc.
972.453.3012
[email protected]

BRIGHTON, Mich, Nov. 24, 2020 (GLOBE NEWSWIRE) — CGE Energy, Inc. (OTCPink: CGEI) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,808,677 to the Company, entitled, “Fluid driven vertical axis turbine.” This patent relates to a fluid driven vertical axis turbine and its remote-controlled blades that fold up and lay flat against the rotor in dangerous, high-wind situations. The patent also covers the manner in which the turbine’s segmented blade joints hydraulically lock together to make a strong, rigid blade, both in the open and closed position.

“The issuance of this sixth patent enhances the strength of our intellectual property protection around our vertical axis wind turbine,” said Bryan Zaplitny, President and CEO of CGE Energy. “This patent further supports our ongoing R&D efforts in bringing unique off-grid power solutions to markets where power availability is an issue.”

To date, CGE Energy has received five U.S. patents as well as one European patent for the technology. These independent patents cover many aspects of the technology, including having a fluid driven turbine that generates power from wind blowing from any direction, its generator and primary components located in the base of the turbine, as well as the turbine’s easy delivery transport method.

In recent months, CGE Energy has expanded its management team that oversees the technology division of CGE Energy and its subsidiaries, as well as expanded its strategic partners to bring this technology to market.

About CGE Energy, Inc.

CGE Energy, Inc.

, and its wholly-owned subsidiary Clean Green Energy, Inc., is a developer of long-term energy projects and self-powered infrastructure which solve the unique energy challenges of their commercial, municipal and nonprofit customers. The Company provides both services and products that enable its customers to reduce their energy consumption; lower their upfront, operating and maintenance costs; and realize environmental benefits.

To learn more visit http://www.cgeenergy.com.

Press Release Contacts

CGE Energy, Inc.
Paul Schneider, VP Marketing
248-446-1344
[email protected]

Forward-Looking Statements

This release may contain “forward-looking statements” that are within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by certain words or phrases such as “may”, “will”, “aim”, “will likely result”, “believe”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “project”, “should”, “will pursue” and similar expressions or variations of such expressions. These forward-looking statements reflect the Company’s current expectations about its future plans and performance. All forward-looking statements included in this release are based on information available to us on the date hereof and speak only as of the date hereof. We undertake no obligation to update or revise publicly any forward-looking statements. Actual results may differ materially from those projected in the forward-looking statements.